Important Questions Relating Personalized Medicines
The global medical market could save over $380 billion with customised healthcare
The term "personalised medicine" describes the process of identifying a patient's best suitable drug based on their genetic makeup.
Future growth will be driven by the trend of personalised medicine. For a very long time, the idea of "right medicine for the right disease" meant giving everyone with the same disease the same medication. However, personalised medicine expands on this idea by prescribing medication for a particular disease while also taking into account each patient's unique genetic makeup and performing treatments that are best suited to their particular condition.
Does it resemble the traditional Chinese medicine approach to diagnosis and treatment in any way?
Yes. It can be claimed that the personalised medicine of Western medicine and the concept of traditional Chinese medicine, which has a long history, have converged.
How should particular individual differences be assessed?
Everybody has a unique genome, and there are variations in aspects related to inheritance and the environment. Therefore, the key advancement in personalised medicine is the detection of gene expression or mutation in order to ascertain whether a certain medication is helpful for a patient.
So, genetic testing is the basis for individual differences?
Indeed. Gene variants are brought on by a combination of inherited, environmental, and lifestyle factors. Physicians can assess a medication's effectiveness for a specific patient by identifying these genetic variations because no single treatment is effective for all patients.
Cancer patients are the main population that personalised medicine focuses on.
Is personalised medicine a part of molecular diagnostics?
The development of personalised medical techniques is made possible by molecular diagnostics, which is a method of personalised medicine. Due to the inability to test for specific genetic diseases before the development of this technology, screening individual patients was fairly difficult. It is now possible to quickly and reliably identify a patient's genes with the aid of molecular diagnostics. Molecular diagnostics, however, are only an additional tool for personalised medication. The goal of personalised medicine is to identify the patient's most appropriate course of treatment after a diagnosis, not to pinpoint a particular disease.
How many diseases can now be identified and treated with personalised medicine?
Currently, cancer therapy is where personalised medicine is most commonly used. Personalised medicine is used to diagnose and treat the majority of new cancer treatments. Cancer patients will soon receive a personalised medical diagnostic to select the best and most efficient treatment for them.
What is the biggest benefit of personalised medicine above traditional diagnostic and therapeutic approaches?
The most significant benefit of personalised medicine is its focus on patient autonomy. First, a rise in treatment efficacy is one of the distinctive advantages. Second, personalised medicine can reduce unneeded side effects of medications by screening the drugs that are most beneficial for the patient, assuring optimal efficacy. We are all aware that every medication carries some level of toxicity. If a medicine is ineffective for a certain patient, that patient does not need to receive that specific treatment, preventing the drug's negative side effects and also conserving money and medical resources. Thirdly, and most importantly for cancer patients, personalised medicine can prevent postponing the start of treatment.
What steps are involved in using personalised therapy techniques to treat cancer?
For instance, a new chemotherapy medication has been shown to be beneficial in treating particular lung cancer patients in the United States and Europe during clinical studies. How can these patients be screened? utilising the newly created EGFR gene test. Patients with lung cancer must undergo an EGFR gene test to determine whether chemotherapy will be effective for them before treatment.
What advantages do medical professionals stand to gain from personalised diagnosis and care?
The ability to provide patients with customised care is the advantage that doctors experience the most directly. Some cancer patients may respond favourably to a given therapy while others may not, as there are numerous medications with varying degrees of effectiveness for cancer patients. Avoiding the drawbacks of a one-size-fits-all strategy, enabling more effective and focused treatment, and enhancing therapeutic outcomes for patients are some advantages of personalised medicine.
Will personalised medicine have high research and development costs?
A mix of medications and supporting diagnostic techniques that are appropriate for certain people make up personalised medicine. Personalised medicine is a tremendous help in the creation of new treatments because it can significantly speed up the lengthy and expensive process of developing new medications. The effectiveness of the drug will rise and the development process will be sped up if people who can react to the drug can be picked out of the patient group. In the context of personalised medicine, the development of novel medications by pharmaceutical firms runs parallel with and complements the development of personalised treatment detection and procedures by diagnostic companies like Kaijie.
What is the largest obstacle to China's development of personalised medicine, in Kaijie's own experience?
Because personalised medicine is a relatively new field and the nation now lacks a policy for it, entry into the market is the biggest hurdle. We are currently learning how to combine diagnosis and treatment from a management standpoint. Drug approval and diagnostic product approval used to be rather distinct processes. However, because personalised medicine is a relatively new profession and a method of diagnosis and treatment, it will take some time to strengthen the necessary laws. The nation has distinctly selected a high point for personalised medicine. The "12th Five-Year Plan" includes the personalised medicine revolution as a major topic for promotion, according to the Ministry of Health. It takes time to research the market and establish pertinent laws in terms of implementation and market development because it is a new field.
In China, personalised medicine is still in its infancy. There is already broad agreement among experts in medicine and clinical research that this is a clear direction for future advancement. However, it is still in its early phases from the perspective of certain technology, goods, and applications. Personalised medicine has grown considerably in recent years in Western nations. There is still a tonne of opportunity for expansion in this sector, despite the fact that the American and European markets began a few years earlier than the domestic market. According to a study, personalised medicine can prevent the waste of healthcare resources and save $380 billion in the global healthcare sector.
What position does KAIJIE currently have in the field of personalised medicine?
Regardless of advances in technology, the breadth of product offerings, or the precision of testing, KAIJIE holds a dominant position in the field of personalised medicine globally. To create innovative products, we have made large investments in personalised medicine research and development.
In China, more than 100 prestigious hospitals make use of KAIJIE technology.
Why did KAIJIE decide to concentrate on developing a personalised medicine platform?
Personalised medicine is a future development trend, making it a very promising topic for us on the one hand. However, from the standpoint of our own competitive advantage, relying on our core technological platform for molecular diagnostics gives us a significant edge when we join the sector of personalised medicine.
Essentially, we have made significant progress in creating the market for personalised medicine over the past year: In terms of clinical applications, more than a hundred of the nation's top hospitals have now embraced the technology and goods of our personalised medical biomarker, Kaijie. We announced the opening of the Kaijie Translational Medicine Centre in Suzhou on September 6th. This facility will cater to the needs of the Chinese market and patients by creating diagnostic tools for personalised medicine.
What distinguishes Kaijie from its competitors in the market?
Our molecular diagnostic platform gives us a distinct technological edge and competitiveness from a technology standpoint. We started in this area quite early in the Chinese market and have made good strides. Although many clinical practitioners now acknowledge that personalised medicine is a more successful treatment strategy, there is still need for improvement in the general public's comprehension of personalised medicine from the standpoint of the patient.
Are there any intentions by Kaijie to better advance individualised medicine?
In order to advance the idea of personalised medicine, Kaijie has partnered with more than a hundred hospitals around the nation. This partnership includes the deployment of products, the provision of training, and the organisation of professional conferences. In order to create new applications, we are also working with hospitals and clinical research organisations.
In order to better provide personalised medicine for unique patients, how should pharmaceutical companies, diagnostic technology companies, and healthcare-related organisations, including government and non-government organisations, collaborate?
The establishment of a novel business model as a result of the development of personalised therapeutic goods in collaboration between pharmaceutical and diagnostic firms is the result of the evolution and demand for personalised medicine. Combining the two elements is necessary for the diagnostic development process. From an industrial perspective, the new business model entails collaboration between diagnostic and pharmaceutical firms to create personalised medical treatments. Health insurance providers' insurance businesses must investigate innovative approaches for personalised medical payment. For instance, insurance companies now mandate the use of personalised medical diagnoses for several diseases in the United States and Europe as a result of the development of personalised medical therapies. Insurance companies won't cover the expense if genetic testing isn't performed on a patient before medication is provided. For pharmaceutical firms, diagnostic businesses, and the government's allocation of medical resources, this emerging area of personalised medicine poses significant obstacles.
What are your thoughts on the potential growth of personalised medicine in China and what is the rationale behind it?
I think personalised medicine in China has a very bright future, which is why we are increasing our investment there, including last week's announcement of the Translational Medicine Center's opening in Suzhou. This is KAIJIE's strategy plan, which will enable us to more effectively serve Chinese patients by stepping up our R&D activities there and generating additional goods that are suited for their needs.
